author-photo

Joanna Pikiel

Gynecologic Oncology Group

36

Papers

2312

Citations

Citation Trend

Filter By

Papers (28) Sort By

Journal Conference Others

Long-term efficacy and safety of CT-P6 versus trastuzumab in patients with HER2-positive early breast cancer: final results from a randomized phase III trial

2021 Breast Cancer Research and Treatment
Show All
- Source
- Cite
- Save
Citations (0)
164 Phase 3 recurrent/metastatic cervical carcinoma trial: subgroup efficacy analysis of cemiplimab versus individual investigator’s choice chemotherapy

2021
Show All
- Source
- Cite
- Save
Citations (0)
991P Treatment-related adverse events (TRAEs) occurring during dostarlimab therapy in the GARNET study

2021 Annals of Oncology
Show All
- Source
- Cite
- Save
Citations (0)
Abstract CT138: Molecular markers in a phase I dose expansion study of PF-06801591 in locally advanced or metastatic non-small-cell lung cancer and urothelial carcinoma

2020 Tumor Biology
Show All
- Source
- Cite
- Save
Citations (0)
ER-/PgR+ breast cancer is a separate entity characterized by distinct phenotype: Comprehensive reevaluation of cases from Polish and Hungarian centers.

2020 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (1)
Overall survival at 5 years of follow-up in a phase III trial comparing ipilimumab 10 mg/kg with 3 mg/kg in patients with advanced melanoma

2020 Journal for ImmunoTherapy of Cancer
Show All
- Source
- Cite
- Save
Citations (14)
73P microRNA expression profiles of single hormone receptor-positive breast cancers

2020 Annals of Oncology
Show All
- Source
- Cite
- Save
Citations (0)
Efficacy and safety of CT-P6 versus reference trastuzumab in HER2-positive early breast cancer: updated results of a randomised phase 3 trial

2019 Cancer Chemotherapy and Pharmacology
Show All
- Source
- Cite
- Save
Citations (10)
190P3-year follow-up of a phase III trial comparing the efficacy and safety of neoadjuvant and adjuvant trastuzumab and its biosimilar CT-P6 in HER2 positive early breast cancer (EBC)

2019 Annals of Oncology
Show All
- Source
- Cite
- Save
Citations (0)
Anti-NaPi2b antibody–drug conjugate lifastuzumab vedotin (DNIB0600A) compared with pegylated liposomal doxorubicin in patients with platinum-resistant ovarian cancer in a randomized, open-label, phase II study

2018 Annals of Oncology
Show All
- Source
- Cite
- Save
Citations (31)